Boston Scientific insider trading
Every open-market purchase and sale by Boston Scientific's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Boston Scientific’s insiders pay?
From May 5, 2010 to August 26, 2026, 35 insiders reported 37 open-market purchases and 103 sales not made under a pre-set plan in Boston Scientific. Twelve months after each purchase was reported, the shares were +14.9% against the S&P 500 on average (median +3.9%), over 29 purchases with a full year of prices; 55% beat the index. After sales, the shares moved −1.5% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 5, 2010 into $30,533 by November 2, 2026, +7.3% a year. It held shares 42% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $20,384 (+4.6% a year), and held throughout $81,636 (+14.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Mario Ernest | Director | 13 | −3.1% (13) | 39% | 4 | +8.1% (4) | November 17, 2015 |
| Thepaut Eric Francis Yves | EVP & Pres, Eur, Mid-East, Afr | 0 | — | — | 12 | −0.7% (12) | May 13, 2024 |
| Ludwig Edward J | Director | 3 | +29.4% (1) | 100% | 6 | −22.2% (6) | August 3, 2026 |
| Nanavaty Maulik | SVP & Pres, Neuromodulation | 0 | — | — | 8 | −0.3% (8) | June 2, 2021 |
| Ballinger Kevin J. | EVP & Pres, Interven Cardio | 0 | — | — | 7 | +7.4% (7) | May 18, 2017 |
| Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | 0 | — | — | 7 | −6.0% (7) | February 6, 2023 |
| Sorenson John Bradley | SVP, Global Supply Chain | 0 | — | — | 7 | −13.7% (7) | February 8, 2022 |
| Carruthers Wendy | SVP, Human Resources | 0 | — | — | 6 | +3.2% (6) | May 3, 2021 |
| Mirviss Jeffrey B. | SVP&Pres, Periph Intervent | 0 | — | — | 6 | +6.1% (6) | March 2, 2017 |
| Connors Nelda J | Director | 1 | −24.1% (1) | 0% | 4 | +3.8% (4) | November 30, 2022 |
| Fitzgerald Joseph Michael | EVP & President, CRM | 0 | — | — | 5 | +5.2% (5) | May 4, 2016 |
| Nicholas Nj Jr | Director | 5 | +29.6% (5) | 40% | 0 | — | November 15, 2012 |
| Abele John E | Other | 3 | +32.1% (3) | 100% | 1 | −5.9% (1) | August 24, 2015 |
| Capello Jeffrey D | EVP & Chief Financial Officer | 0 | — | — | 4 | −7.5% (4) | December 2, 2013 |
| Dawkins Keith D | EVP, Global Chief Med. Off. | 0 | — | — | 4 | −7.4% (4) | March 2, 2017 |
| Habiger David C | Director | 3 | — | — | 0 | — | August 7, 2026 |
| Mahoney Michael F | Chairman, President & CEO | 3 | +61.3% (2) | 100% | 0 | — | August 5, 2026 |
| Pedersen John B. | Pres, Uro & Women's Health | 0 | — | — | 3 | −26.3% (3) | August 15, 2011 |
| Pierce David A | EVP Pres MedSurg | 0 | — | — | 3 | +1.4% (3) | February 22, 2022 |
| Sununu John E | Director | 0 | — | — | 3 | +22.6% (3) | May 15, 2015 |
| Eddy Jodi Euerle | SVP, Chief Info & Digital Off. | 0 | — | — | 2 | −17.1% (2) | August 27, 2020 |
| Fujimori Yoshiaki | Director | 0 | — | — | 2 | −37.2% (2) | July 30, 2025 |
| Johnson Kristina M | Director | 0 | — | — | 2 | +16.9% (2) | May 19, 2015 |
| Lance Jean Fitterer | SVP & Chief Compliance Officer | 0 | — | — | 2 | +21.0% (2) | November 12, 2014 |
| Bartlett Katharine T | Director | 1 | −21.4% (1) | 0% | 0 | — | November 30, 2011 |
| Brennan Daniel J. | EVP and CFO | 0 | — | — | 1 | +37.1% (1) | February 20, 2024 |
| Dockendorff Charles J | Director | 1 | +20.2% (1) | 100% | 0 | — | February 16, 2016 |
| Kucheman William | Chief Executive Officer | 1 | +85.1% (1) | 100% | 0 | — | August 2, 2012 |
| Morano Susan E | Director | 1 | — | — | 0 | — | August 26, 2026 |
| Pegus Cheryl | Director | 1 | — | — | 0 | — | May 21, 2026 |
| Prange Karen | SVP&Pres, Uro & Pelvic Health | 0 | — | — | 1 | +22.6% (1) | February 9, 2016 |
| Pratt Timothy A. | EVP, GC & Chief Admin Officer | 0 | — | — | 1 | −7.8% (1) | November 21, 2013 |
| Pucel Kenneth | EVP, Glob Ops, Qual & Tech | 0 | — | — | 1 | +10.3% (1) | February 21, 2014 |
| Wichmann David S | Director | 1 | +15.9% (1) | 100% | 0 | — | November 16, 2021 |
| Woodworth Emily | SVP, Global Controller and CAO | 0 | — | — | 1 | −7.1% (1) | December 2, 2024 |
When several insiders traded Boston Scientific
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Boston Scientific in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged +7.3% against the index. After 10 selling crowds, −0.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| May 29, 2026 | 3 buying | −5.0% | not yet | not yet |
| June 30, 2021 | 3 selling | +0.8% | −11.3% | −2.2% |
| August 31, 2020 | 3 selling | −23.3% | −15.5% | −21.1% |
| September 30, 2019 | 3 selling | +1.8% | −7.6% | −21.4% |
| November 30, 2018 | 4 selling | +4.4% | +2.5% | −1.4% |
| September 29, 2017 | 3 selling | −21.8% | −10.6% | +15.4% |
| March 31, 2017 | 3 selling | +8.4% | +9.7% | −2.3% |
| May 31, 2016 | 3 selling | +2.4% | −14.8% | +1.6% |
| January 29, 2016 | 3 selling | +18.0% | +25.3% | +16.1% |
| February 27, 2015 | 3 selling | +7.4% | +4.8% | +6.7% |
| June 28, 2013 | 3 selling | +18.5% | +14.3% | +13.4% |
| August 31, 2012 | 3 buying | +2.2% | +26.6% | +94.1% |